Los puntos clave no están disponibles para este artículo en este momento.
Future research should be directed to individualize regimens and protect these recent breakthroughs by preventing and identifying the selection of drug resistance and providing widespread, affordable, patient-centred access to new treatment options for all people affected by TB.
Motta et al. (Fri,) studied this question.